How is DSIP dosed for sleep, and how is the powder mixed?
Draw to
unitsmL
0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe
Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.
Save to Milligram
Open in Milligram shows once the calculator has a result.
Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.
Open in Milligram is off while the draw is under one unit. Check the dose and its unit.
Open in Milligram adds DSIP (Delta Sleep-Inducing Peptide) and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.
No label gives a DSIP dose for sleep: the chronic-insomnia trials gave 25 or 30 nmol/kg intravenously, FDA counts 25 to 150 nmol/kg intravenously in 209 subjects for 1 to 15 days across its human studies, withdrawal studies included, and it found no clinical study of the subcutaneous route.1234
The guide's example
300 mcg of DSIP (Delta Sleep-Inducing Peptide) from a 5 mg vial mixed with 3 mL is 18 units on a U-100 syringe.
Every vial at a glance. Pick a cell to draw it on the syringe.
| Vial | 1 mL of water | 2 mL of water | 3 mL of water |
|---|---|---|---|
| 5 mg | 5 mg/mL: 100 mcg is 2 units, 300 mcg is 6 units | 2.5 mg/mL: 100 mcg is 4 units, 300 mcg is 12 units | 1.667 mg/mL: 100 mcg is 6 units, 300 mcg is 18 units |
Vials and units per dose
The table is maths only: no label gives a concentration, and its dose rows are the app's own example amounts, not doses from any label or trial, which dosed by body weight.4 FDA also records one website offering emideltide 2 mg/mL in a 4 mL vial, sold in a “ready to use” kit.4 FDA and the trials name no water volume for mixing a vial of DSIP powder. For intravenous use, FDA records two withdrawal studies: Backmund et al. 1998 diluted 35 nmol/kg in 4 mL of 0.9% saline, and Dick et al. 1984, in 107 subjects with withdrawal syndrome, gave 25 nmol/kg in 10 mL of physiological serum.4 FDA describes Deltaran, from a Russian Academy of Sciences institute, as a lyophilized mix of emideltide free base and glycine (1:10 by weight) in saline, in ampoules of 0.3 mg emideltide and 3.0 mg glycine, in its review of a mouse study (Popovich et al. 2003), not a human trial.4 FDA reports the free base soluble in water at 0.5 mg/mL and the acetate at 10 mg/mL in phosphate buffered solution, with 1,000 mcg/mL not expected to be an issue for the acetate; in its conclusion it says that, given their limited solubility in water, it is unclear how the 1,000 mcg/mL injection could be made without a co-solvent.4 Every mix in the table is above the free base's 0.5 mg/mL water solubility.4
Worked example, as maths only: 300 mcg from a 5 mg vial mixed with 3 mL is 18 units on a U-100 syringe; the trials dosed by body weight, such as 25 nmol/kg, which FDA's briefing gives as 21.23 mcg/kg in one study and as 21.4 µg/kg in another.4
300 mcg of DSIP (Delta Sleep-Inducing Peptide) from a 5 mg vial mixed with 3 mL is 18 units on a U-100 syringe.
Doses and schedules in the trials
FDA found human data only for intravenous administration: 25 to 150 nmol/kg in 209 subjects for 1 to 15 days.4
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Schneider-Helmert and Schoenenberger 19815 | 25 nmol/kg intravenously5, over 4 minutes immediately before bedtime, against placebo in a randomised, double-blind crossover over three nights, in the sequence placebo-emideltide-placebo or the reverse4 | 6 middle-aged chronic insomniacs | 3 nights1 |
| Monti 19876 | 25 nmol/kg or placebo intravenously in a double-blind crossover during four nights6, repeated twice in FDA's slide1 | 6 subjects with insomnia1 | 4 nights, 4-day washout |
| Bes 19922 | 25 nmol/kg intravenously or a glucose placebo, double-blind, in the afternoon before the 3rd, 4th and 5th night2 | 16 chronic insomniacs, half on each | 5 nights |
| Schneider-Helmert 19863 | 6 x 30 nmol/kg intravenously over one week3; slide: 30 nmol/kg x 5 nights1 | 18 chronic insomniacs, middle-aged and older | one week, then one week of follow-up |
| Schneider-Helmert 19877 | Slide: 30 nmol/kg x 7 nights1; briefing: seven IV injections of 30 nmol/kg on nights 3 through 9, no placebo arm, compared with an external control group of healthy subjects4; the paper gives no dose7 | 14 middle-aged chronic insomniacs | 7 nights |
Monti 1987 found fewer awakenings and less waking time under DSIP but no significant differences against baseline or placebo nights, and concluded that sleep improvement under DSIP is of little clinical significance.61 Schneider-Helmert's 1987 trial reports substantially improved night sleep, and his 1986 study normal sleep patterns in the whole sample at the end; FDA's slide marks both as compared to externally controlled healthy subjects, and its briefing says the 1987 study had no placebo arm.7314 FDA's briefing converts 25 nmol/kg to 21.23 mcg/kg in Schneider-Helmert et al. 1981, a first-in-human placebo-controlled pilot in six middle-aged otherwise healthy subjects given IV over 20 minutes, to 21.3 µg/kg in Schneider-Helmert and Schoenenberger 1983, and to 21.4 µg/kg in Dick et al. 1984 in withdrawal patients.4
No trial gives a course longer than 15 days or a cycle length for repeating one, and no fetched source names an injection site.4
Storage
FDA reports bulk free-base powder stable for three years at -20°C, or two years at 4°C.4 Those are bulk-substance figures for the free base; for the acetate, FDA reports the powder stable for four years at -20°C and a bulk solution keeping its efficacy for more than one month at -20°C, notes that peptides such as emideltide acetate can be extremely sensitive to formulation, process and environmental conditions, which may lead to aggregation and degradation, and gives no storage time for a mixed vial.4
Frequently asked questions
Is there an FDA-approved label for DSIP?
FDA says emideltide is not a component of an FDA-approved drug.4
References
- US FDA. July 23-24, 2026 Pharmacy Compounding Advisory Committee (PCAC) Meeting. 2026. fda.gov
- Neuropsychobiology (PubMed abstract). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. 1992. pubmed.ncbi.nlm.nih.gov
- European neurology (PubMed abstract). Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs. 1986. pubmed.ncbi.nlm.nih.gov
- US FDA. FDA Briefing Document. 2026. fda.gov
- Experientia (PubMed abstract). The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. 1981. pubmed.ncbi.nlm.nih.gov
- International journal of clinical pharmacology research (PubMed abstract). Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs. 1987. pubmed.ncbi.nlm.nih.gov
- European neurology (PubMed abstract). Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia. 1987. pubmed.ncbi.nlm.nih.gov